This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Michael Kopach, Ph.D.
Senior Research Advisor at Eli Lilly and Company


Mike earned a Ph. D. in Organic chemistry from the University of Virginia in 1995 under the guidance  of Prof. W.D. Harman.  He then completed postdoctoral studies in natural product synthesis at Colorado State University with  Prof. A. I. Meyers. Mike began his industrial career in 1997 at Roche where his primary responsibilities included development and implementation of commercial processes for Nelfinavir, Xenical and Enfuvirtide - the first synthetic peptide produced on tonnage scale.   In  2001, Mike joined Eli Lilly and Company and has led several small molecule  phase 1 to phase 3 R&D projects. Throughout his industrial career Mike has led research teams applying green chemistry principles to product research and development, and has published several collaborative articles in this field.  For the past decade Mike has represented Eli Lilly and Company at the ACS  Green Chemistry Institute® Pharmaceutical Roundtable including serving a two year term as co-chair from 2011-2013 and another from 2017 - present.   After a fourteen year career within Lilly Small Molecule R&D, Mike now has responsibility for multiple synthetic peptide projects.  In this area Mike lead an internal infrastructure build to bring peptide synthesis capability in house.

Agenda Sessions

  • Tirzepatide, A Once-weekly Dual GIP and GLP-1 Receptor Agonist: CMC Considerations for Development of a High Volume Complex Synthetic Peptide